QA: DYNAVAX TECHNOLOGIES CORP in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001029142_2023_DYNAVAX_TECHNOLOGIES_CORP.pdf

Logs

info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001029142, DYNAVAX TECHNOLOGIES CORP

  xvar xval
0 AssetsCurrent 916,985,000
1 IntangibleAssetsNetIncludingGoodwill 2,006,000
2 PropertyPlantAndEquipmentNet 37,596,000
3 remainder_Assets 29,263,000
4 LiabilitiesCurrent 150,074,000
5 LiabilitiesNoncurrent 33,185,000
6 remainder_Liabilities 221,578,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 131,408,000
9 ResearchAndDevelopmentExpense 46,600,000
10 remainder_Expenses 267,227,000
11 remainder_Revenues 730,368,000
12 remainder_NetIncome 8,023,000
13 remainder_ComprehensiveNetIncome -3,172,000
  yvar yval
0 Assets 985,850,000
1 Liabilities 404,837,000
2 Expenses 445,235,000
3 Revenues 730,368,000
4 StockholdersEquity 581,013,000
5 NetIncome 293,156,000
6 ComprehensiveNetIncome 291,570,000
7 BaseVar 1,288,742,500
8 EconomicCapitalRatio 1.86

Edgar->Model Mapping

Feature Distribution

Change over Time